SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXeris Biopharma Regulatory News (0A8E)

Share Price Information for Xeris Biopharma (0A8E)

Share Price is delayed by 15 minutes
Get Live Data
6.88    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: $1.21b
0A8E Live PriceLast checked at - London Stock Exchange

Intraday Xeris Biopharma Share Chart

  • This share is an international stock.

Xeris Pharmaceuticals, Inc 8.3

9 Jun 2021 13:59

RNS Number : 3619B
J.P. Morgan Securities LLC
09 June 2021
Β 

Ap19

Β 

Β 

Β 

FORMΒ 8.3

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 8.3Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DEALINGSΒ BYΒ PERSONSΒ WITHΒ INTERESTSΒ INΒ RELEVANTΒ SECURITIESΒ REPRESENTINGΒ 1%Β ORΒ MORE

Β 

1. KEYΒ INFORMATION

Β 

Name of person dealing (Note 1)

J.P. Morgan Securities LLC

Company dealt in

Xeris Pharmaceuticals, Inc.

Class of relevant security to which the dealings being disclosed relate (Note 2)

$0.001 common stock

Date of dealing

08 June 2021

Β 

2. INTERESTSΒ ANDΒ SHORTΒ POSITIONS

Β 

(a) InterestsΒ andΒ shortΒ positionsΒ (followingΒ dealing)Β inΒ theΒ classΒ ofΒ relevantΒ securityΒ dealtΒ inΒ (NoteΒ 3)

Β 

Long

Short

Β 

Number

Β 

(%)

Number

Β 

(%)

(1) Relevant securities

4,132,967 6.23

Β 

733,024 1.10

Β 

(2) Derivatives (other than options)

590,302 0.89

Β 

Β 

(3) Options and agreements to purchase/sell

Β 

Β 

Total

4,723,269 7.12

Β 

733,024 1.10

Β 

Β Β Β Β Β Β Β 

Β 

Β 

Ap20

Β 

Β 

1. DEALINGSΒ (NoteΒ 4)

Β 

(a) PurchasesΒ andΒ sales

Β 

Β 

Purchase/sale

Β 

Number of relevant securities

Β 

Price per unit (USD)

Β 

(Note 5)

Purchases

Β 

Sales

Sales

9,300

Β 

Β 9,300

Β 291

3.9000 USD

3.9000 USD

3.8966 USD

Β 

Β 

Β 

Β 

Β 

Β 

(b) DerivativesΒ transactionsΒ (otherΒ thanΒ optionsΒ transactions)

Β 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(USD) (Note 5)

Β 

Β 

Β 

Β 

Β 

Β 

(c) OptionsΒ transactionsΒ inΒ respectΒ ofΒ existingΒ relevantΒ securities

Β 

Β 

(i) Writing,Β selling,Β purchasingΒ orΒ varying

Β 

Β 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

(ii) Exercising

Β 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

Β 

Β 

Β 

Β 

Β 

(d) OtherΒ dealingsΒ (includingΒ transactionsΒ inΒ respectΒ ofΒ newΒ securities)Β (NoteΒ 4)

Β 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Β 

Β 

Β 

Β 

Β 

Ap21

Β 

2. OTHERΒ INFORMATION

Β 

Agreements,Β arrangementsΒ orΒ understandingsΒ relatingΒ toΒ optionsΒ orΒ derivatives

Β 

Β 

Β 

Β 

FullΒ detailsΒ ofΒ anyΒ agreement,Β arrangementΒ orΒ understandingΒ betweenΒ theΒ personΒ disclosing andΒ anyΒ otherΒ personΒ relatingΒ toΒ theΒ votingΒ rightsΒ ofΒ anyΒ relevantΒ securitiesΒ underΒ anyΒ option referredΒ toΒ onΒ thisΒ formΒ orΒ relatingΒ toΒ theΒ votingΒ rightsΒ orΒ futureΒ acquisitionΒ orΒ disposalΒ ofΒ anyrelevantΒ securitiesΒ toΒ whichΒ anyΒ derivativeΒ referredΒ toΒ onΒ thisΒ formΒ isΒ referenced.Β IfΒ none,Β this shouldΒ beΒ stated.

Β 

None

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

IsΒ aΒ SupplementalΒ FormΒ 8Β attached?Β (NoteΒ 9) Β NO

Β 

Date of disclosure

Β 09 June 2021

Contact name

Alwyn Basch

Telephone number

0207 742 7407

If a connected EFM, name of offeree/offeror with which connected

N/A

If a connected EFM, state nature of connection (Note 10)

N/A

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
ISEKZGGVZLRGMZM
Date   Source Headline
7th Oct 20213:09 pmRNSXeris Pharmaceuticals, Inc 8.3
6th Oct 20212:43 pmRNSXeris Pharmaceuticals, Inc 8.3
6th Oct 20212:42 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
5th Oct 20215:06 pmRNSXeris Pharmaceuticals, Inc 8.3 Amend
5th Oct 20213:15 pmRNSXeris Pharmaceuticals, Inc 8.3
4th Oct 20211:04 pmRNSXeris Pharmaceuticals, Inc 8.3
1st Oct 20213:05 pmRNSXeris Pharmaceuticals, Inc 8.3
1st Oct 202110:14 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
30th Sep 20215:07 pmRNSXeris Pharmaceuticals, Inc 8.3
30th Sep 20212:58 pmRNSXeris Pharmaceuticals, Inc 8.3
30th Sep 202110:22 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
29th Sep 20212:36 pmRNSXeris Pharmaceuticals, Inc 8.3
28th Sep 20212:22 pmRNSXeris Pharmaceuticals, Inc 8.3
28th Sep 20212:21 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
28th Sep 20212:19 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
27th Sep 202112:27 pmRNSXeris Pharmaceuticals, Inc 8.3
24th Sep 20214:35 pmRNSXeris Pharmaceuticals, Inc 8.3
24th Sep 20211:05 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
23rd Sep 20212:35 pmRNSXeris Pharmaceuticals, Inc 8.3
23rd Sep 20212:18 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
22nd Sep 20213:00 pmRNSXeris Pharmaceuticals, Inc 8.3
22nd Sep 20212:12 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
22nd Sep 202112:18 pmRNSForm 8.3 - XERIS PHARMACEUTICALS INC
21st Sep 20213:03 pmRNSXeris Pharmaceuticals, Inc 8.3
21st Sep 20212:17 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
21st Sep 20211:40 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
20th Sep 20211:53 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
20th Sep 202112:29 pmRNSXeris Pharmaceuticals, Inc 8.3
20th Sep 202112:14 pmGNWInvesco ltd: Form 8.3 - Xeris Pharmaceutical Inc.
17th Sep 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
17th Sep 20212:51 pmRNSXeris Pharmaceuticals, Inc 8.3
17th Sep 20212:05 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
17th Sep 20211:13 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc.
16th Sep 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
16th Sep 20212:46 pmRNSXeris Pharmaceuticals, Inc 8.3
16th Sep 20211:58 pmGNWInvesco Ltd: Form 8.3 - Xeris Pharmaceutical Inc
16th Sep 202110:52 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
15th Sep 20211:58 pmRNSXeris Pharmaceuticals, Inc 8.3
15th Sep 202111:15 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
15th Sep 202111:14 amGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
14th Sep 20212:24 pmRNSXeris Pharmaceuticals, Inc 8.3
14th Sep 20211:56 pmRNSMan Group PLC : Form 8.3 - Strongbridge biopharma plc
14th Sep 20211:03 pmRNSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc.
13th Sep 202112:22 pmRNSXeris Pharmaceuticals, Inc 8.3
13th Sep 202112:15 pmGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
10th Sep 20212:42 pmRNSXeris Pharmaceuticals, Inc 8.3
10th Sep 20217:21 amGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
9th Sep 20211:49 pmRNSXeris Pharmaceuticals, Inc 8.3
9th Sep 202111:15 amRNSForm 8.3 - Xeris Pharmaceuticals, Inc
9th Sep 202111:13 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.